|
Friday, December 12th 2008
InNexus Completes Previously Announced Private Placement
Monday, November 17th 2008
InNexus Biotechnology CEO Named Business Leader of the Year
Friday, November 7th 2008
InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and announces $1.25 Million Private Placement
Thursday, October, 30 2008
InNexus Biotechnology Receives Patent Grants in Europe
Tuesday, October, 28 2008
InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
Monday, September, 29 2008
InNexus Biotechnology CEO To Present at BioContactQuebec 2008
Friday, September, 19 2008
St. Joseph's Hospital and InNexus Biotechnology Enter Collaborative Partnership
Tuesday, September 16, 2008
InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
Tuesday, September 9, 2008
InNexus Biotechnology Strengthens Patent Team with New Leadership
Monday, September 8, 2008
InNexus Biotechnology CEO To Present at The Wall Street Analyst Forum in NYC
Thursday, August 7, 2008
InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
Wednesday, August 6, 2008
InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds
|
|
InNexus Biotechnology Inc. is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking technology (DXL™) improving the potency of existing antibody products while opening new markets and disease applications.
»Recent Letter from the Chairman
»Watch BNN TV interview with CEO - Jeff Morhet
»Meet the Scientific Advisory Board
»See What InNexus Presented at AACR 2008 in San Diego
|
|
